A Study in Myeloproliferative Disorders

The purpose of the study is to learn:

1. How much and how often LY2784544 should be given to patients

2. What is the safety profile of LY2784544 and any side effects that might be associated
with it

3. How LY2784544 is taken up, distributed, broken down, and passed out of your body

4. Whether LY2784544 can help patients with myeloproliferative disorders

5. If any markers in the blood (biomarkers) can identify patients who will respond better
to the study drug.

The planned duration of the study is not fixed. The length of time patients participate in
the study will be determined by the investigator/study doctor.

Part A of the study is to determine the dose of the study drug. Part A is divided into two
sections, A1 and A2. In Part A1, patients will be given study drug without a lead-in period.
In Parts A2 and B, patients will have a lead-in period of 2 or 4 weeks with a low dose of
LY2784544 prior to taking a higher dose of LY2784544. Part B of the study is to confirm the
safety of the dose and schedule.

Inclusion Criteria:

- Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or
myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic
criteria for myeloproliferative neoplasms and meet the following additional sub-type
specific criteria:

A. PV: has failed or is intolerant of standard therapies or refuses to take standard
medications

B. ET: has failed or is intolerant of standard therapies or refuses to take standard
medications

C. MF (patients with MF must meet at least one of the following):

i. has intermediate or high-risk MF according to the Lille scoring system; or

ii. has symptomatic MF with spleen greater than 10 cm below left costal margin; or

iii. has post-polycythemic MF; or

iv. has post-ET MF

- Have a quantifiable JAK2 V617F mutation

- Have discontinued all previous approved therapies for myeloproliferative disorders,
including any chemotherapy, immunomodulating therapy (for example, thalidomide,
interferon-alpha), immunosuppressive therapy (for example, corticosteroids greater
than 10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin,
thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and
recovered from the acute effects of therapy. Hydroxyurea used to control blood cell
counts is permitted at study entry if the subject has been maintained on a stable dose
for at least 4 weeks. Low-dose acetylsalicylic acid (aspirin) is permitted as well

Exclusion Criteria:

- Have received treatment within 14 days of the initial dose of study drug with an
experimental agent that has not received regulatory approval for any indication

- Are currently being treated with agents that are metabolized by CYP3A4 with a narrow
therapeutic margin (for example, alfentanil, cyclosporine, diergotamine, ergotamine,
fentanyl, pimozide, quinidine, sirolimus, and tacrolimus) or CYP2B6 (for example,
cyclophosphamide, ifosfamide, tamoxifen, efavirenz, propofol, methadone, and
bupropion)

- Are currently being treated with warfarin or one of its derivatives which is known to
alter levels of protein C or protein S. An exception to this criterion will be allowed
for patients with a prior history of Budd-Chiari Syndrome who are being treated with
warfarin or one of its derivatives